insights_auto
Why is ADAPY down 3,79%?
Dive Deeperchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
0,028 $
arrow_downward
-3,79%(-0,0011) 1D
7 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
0,02 $
High
0,03 $
Low
0,02 $
Mkt. cap
7,15 մլն
Avg. vol.
211,23 հզր
Volume
136,96 հզր
52-wk high
0,28 $
52-wk low
0,00 $
Beta
0,75
Shares outstanding
265,05 մլն
No. of employees
272
Open
0,02 $
High
0,03 $
Low
0,02 $
Mkt. cap
7,15 մլն
Avg. vol.
211,23 հզր
Volume
136,96 հզր
52-wk high
0,28 $
52-wk low
0,00 $
Beta
0,75
Shares outstanding
265,05 մլն
No. of employees
272
News stories
From web sources and news partners
Simply Wall Street
·
15 րոպե առաջ
How Trial Enrollment Completion At Pulse Biosciences (PLSE) Has Changed Its Investment Story
Blockhead
·
28 րոպե առաջ
FDUSD Issuer First Digital to Go Public on Nasdaq in $250 Million SPAC Deal
Mitrade
·
4 րոպե առաջ
Strip Out AI and the S&P 500 Looks Very Different, Goldman Index Shows
Investor's Business Daily
·
1 ժամ առաջ
Futures: Memory Giant's Earnings Surge, But Miss Views
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR